https://www.selleckchem.com/products/LBH-589.html
Mean estimate (95% confidence intervals) for the disease progression rate was 0.319 (0.271 - 0.411) month-1 . Treatment effect on IPSS (DELTA) was found to be 0.0605, 0.0139 and 0.0310 month-1 for placebo, tamsulosin and combination therapy, respectively. In addition, it appears that individual trajectories can be clustered together into different phenotypes based on the underlying disease progression rate. CONCLUSIONS The availability of a drug-disease model provides a basis for evaluating interindividual differences in disease progres
Like
Comment
Share
